Recursion Pharmaceuticals (RXRX) reached $3.11 at the closing of the latest trading day, reflecting a +1.63% change compared to its last close.

Resident Evil's Spencer Mansion is a 30 year-old design miracle built on a spiral of progression that takes us deep into ...

SPDR S&P Biotech ETF (NYSEARCA:XBI) is built around a deceptively simple idea: give every biotech company roughly equal footing, regardless of size. That equal-weight structure separates it from ...

A month has gone by since the last earnings report for Recursion Pharmaceuticals (RXRX). Shares have lost about 16.5% in that time frame, underperforming the S&P 500. Will the recent negative trend ...

Nvidia sold its entire 7.71 million share stake in Recursion Pharmaceuticals by December 31, 2025 Recursion stock swung 14% lower intraday Wednesday before closing 2% higher ARK Invest bought 1.25 ...

According to God of Prompt on Twitter, the implementation of verification loops in AI models—where the system recursively checks its answers using different reasoning modes such as backward ...

Health Discovery Corp. company and executive profile by Barron's. View the latest HDVY company infomation and executive bios.

Recursion Pharmaceuticals' AI-based approach has the potential to transform the pharmaceutical industry. However, it is still chasing clinical wins that would demonstrate the power of its strategy.

When I last covered the self-styled TechBio company Recursion Pharmaceuticals, Inc. (RXRX) in early October, I was attempting to find reasons why the company's share price was on the rise, up from ~$4 ...

Recursion Pharmaceuticals (RXRX) added ~11% in the morning trading on Wednesday after J.P. Morgan upgraded the AI-driven biotech to Overweight from Neutral, citing a blockbuster sales potential for ...